Brief: TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial
03/06/2024 14:33
June 3 (Reuters) - TriSalus Life Sciences Inc TLSI.O :
* TRISALUS LIFE SCIENCES HIGHLIGHTS CLINICAL DATA FROM PHASE
1B
PERIO-02 TRIAL, STUDYING DELIVERY OF NELITOLIMOD VIA
PRESSURE-ENABLED DRUG DELIVERY IN PATIENTS WITH HEPATOCELLULAR
CARCINOMA OR INTRAHEPATIC CHOLANGIOCARCINOMA AT 2024 ASCO ANNUAL
MEETING
* TRISALUS LIFE SCIENCES: HEPATIC ARTERIAL INFUSION OF
NELITOLIMOD
WELL TOLERATED
* TRISALUS LIFE SCIENCES: HEPATIC ARTERIAL INFUSION OF
NELITOLIMOD
ASSOCIATED WITH ENCOURAGING IMMUNOLOGIC ACTIVITY IN PATIENTS
WITH HCC, ICC
Source text for Eikon: ID:nBw4fSQ0Ka
Further company coverage: TLSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TriSalus Life Sciences
See all newsTriSalus jumps after FDA clears liver treatment device
Brief: Trisalus Life Sciences Receives FDA Clearance For Trinav Advance
TriSalus Life Sciences Inc reports results for the quarter ended June 30 - Earnings Summary
TriSalus Life Sciences Q2 revenue beats estimates
TriSalus Life Sciences Inc expected to post a loss of 15 cents a share - Earnings Preview